The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Viral And Non-Viral Vector Manufacturing Market During 2026–2030?

The viral and non-viral vector manufacturing market size has experienced substantial expansion in recent years. It is anticipated to increase from $10.28 billion in 2025 to $12.4 billion in 2026, reflecting a compound annual growth rate (CAGR) of 20.7%. The historical market growth can be attributed to key factors such as advancements in gene therapy research, a rise in clinical trial engagements, the expansion of biopharmaceutical manufacturing facilities, growing demand for viral vectors, particularly in oncology, and the availability of specialized manufacturing expertise.

The viral and non-viral vector manufacturing market size is projected to experience substantial growth over the coming years, with expectations to reach $26.83 billion by 2030 at a compound annual growth rate (CAGR) of 21.3%. This anticipated expansion during the forecast period is driven by several factors, including the increasing commercialization of gene and cell therapies, rising investments in vaccine development, the expansion of CDMO partnerships, a growing emphasis on scalable and flexible manufacturing, and an increase in regulatory approvals for advanced therapies. Concurrently, major trends expected during this period include the increasing scale-up of viral vector production capacity, a rising demand for non-viral delivery systems, the growing adoption of modular manufacturing platforms, the expansion of contract vector manufacturing services, and an enhanced focus on process standardization and quality control.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12570&type=smp

Which Major Factors Are Driving The Expansion Of The Viral And Non-Viral Vector Manufacturing Market?

An increase in clinical trials is anticipated to stimulate the expansion of the viral and non-viral vector manufacturing markets moving ahead. These trials involve investigations with human subjects to assess the safety, effectiveness, and possible adverse reactions of a medical procedure, therapy, or medication. The production of viral and non-viral vectors is crucial for facilitating gene therapy clinical trials, offering the essential means to introduce therapeutic genes into patients and guaranteeing the safety, quality, and capacity of these vectors across all trial stages. For example, data from December 2023, sourced from ClinicalTrials.gov, a US-based online platform managed by the US National Library of Medicine that details clinical trials, indicated that in the year 2022, a total of 437,515 clinical trials were registered, with 56,561 of these having reached completion. By December 20, 2023, both the number of registered and completed trials had risen. To be precise, 476,626 clinical trials were registered, and 61,504 trials had already concluded. Consequently, the increasing volume of clinical trials is propelling the expansion of the viral and non-viral vector manufacturing markets.

How Are The Various Segments Of The Viral And Non-Viral Vector Manufacturing Market Categorized?

The viral and non-viral vector manufacturing market covered in this report is segmented –

1) By Vector Type: Viral Vector, Non-Viral Vector

2) By Disease: Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases

3) By Application: Gene Therapy, Vaccinology, Cell Therapy, Other Applications

Subsegments:

1) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Other Viral Vectors

2) By Non-Viral Vector: Plasmid DNA, Lipid-Based Vectors, Nanoparticles, Electroporation-Based Vectors, Other Non-Viral Vectors

What Trends Are Affecting The Expansion Of The Viral And Non-Viral Vector Manufacturing Market?

Major companies engaged in the viral and non-viral vector manufacturing market are focusing on partnerships to boost their profitability. Collaborative alliances in viral and non-viral vector manufacturing involve biopharmaceutical firms, CDMOs, research institutions, and technology providers working jointly to improve the efficiency, safety, and scalability of non-viral vector development and production. For example, in September 2023, NecstGen, a Netherland-based CDMO that provides comprehensive support for all developers in the Cell and Gene Therapy field, collaborated with ProteoNic BioSciences, a Netherland-based technology provider for producing complex therapeutic proteins. They launched ProteoNic’s 2G UNic premium vector technology. The successful use of this technology has enhanced the development of lentiviral (LV) vectors, increasing functional viral particle titers and directly improving process efficiency, thereby increasing the cost-effectiveness and accessibility of therapies. This versatile technology extends to various applications, including gene therapy viral vector production, mRNA therapeutics, and transient protein production. By advancing AAV and LV viral vector manufacturing technology for both transient systems and stable producer cell lines, this development has the potential to benefit viral vector manufacturing for gene therapies and non-vector processes, offering potential benefits across diverse applications.

Which Major Firms Influence Developments In The Viral And Non-Viral Vector Manufacturing Market?

Major companies operating in the viral and non-viral vector manufacturing market are Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.

Read the full viral and non-viral vector manufacturing market report here:

https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

Which Region Currently Holds The Largest Share Of The Viral And Non-Viral Vector Manufacturing Market?

North America was the largest region in the viral and non-viral vector manufacturing market in 2025. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Viral And Non-Viral Vector Manufacturing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12570&type=smp

Browse Through More Reports Similar to the Global Viral And Non-Viral Vector Manufacturing Market 2026, By The Business Research Company

Viral Vector Manufacturing Global Market Report

https://www.thebusinessresearchcompany.com/report/viral-vector-manufacturing-global-market-report

Oral Expectorant Global Market Report

https://www.thebusinessresearchcompany.com/report/oral-expectorant-global-market-report

Viral Inactivation Global Market Report

https://www.thebusinessresearchcompany.com/report/viral-inactivation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.